Associated Genetic Biomarkers
Phosphatidylinositol 3-kinase, catalytic subunit type 3 (PIK3C3) is a gene that encodes a protein that functions as a catalytic subunit of the PI3K protein complex. The protein facilitates the formation of phosphatidylinositol 3-phosphate - a protein that regulates the developmental stages of autophagosomes. The protein is also involved in the transport of lysosomal enzymes and cytokinesis. Missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
PIK3C3 is altered in 1.22% of all cancers with lung adenocarcinoma, colon adenocarcinoma, endometrial endometrioid adenocarcinoma, cutaneous melanoma, and high grade ovarian serous adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in PIK3C3 are PIK3C3 Mutation (0.87%), PIK3C3 Loss (0.18%), PIK3C3 Amplification (0.11%), PIK3C3 R539H (0.01%), and PIK3C3 R210Q (0.01%) .
PIK3C3 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains PIK3C3 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with PIK3C3 status in the inclusion eligibility criteria most commonly target malignant solid tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is PIK3C3 Mutation .
Paxalisib and radiation therapy are the most frequent therapies in trials with PIK3C3 as an inclusion criteria .
Significance of PIK3C3 in Diseases
Malignant Solid Tumor +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.